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rationale: The activity of the transcription factor, hypoxia-inducible factor (HIF)-1α, 
is a common driver of a number of the pathways involved in the aggressiveness of 
glioblastomas (GBMs), and it has been suggested that the reduction in this activity 
observed, soon after the administration of temozolomide (TMZ), can be a biomarker 
of an early response in GBM models. As HIF-1α is a tightly regulated protein, studying 
the processes involved in its downregulation could shed new light on the mechanisms 
underlying GBM sensitivity or resistance to TMZ.
Methods: The effect of HIF-1α silencing on cell responsiveness to TMZ was assessed 
in four genetically different human GBM cell lines by evaluating cell viability and apopto-
sis-related gene balance. LAMP-2A silencing was used to evaluate the contribution of 
chaperone-mediated autophagy (CMA) to the modulation of HIF-1α activity in TMZ-
sensitive and TMZ-resistant cells.
results: The results showed that HIF-1α but not HIF-2α activity is associated with GBM 
responsiveness to TMZ: its downregulation improves the response of TMZ-resistant 
cells, while blocking CMA-mediated HIF-1α degradation induces resistance to TMZ in 
TMZ-sensitive cells. These findings are in line with the modulation of crucial apopto-
sis-related genes.
conclusion: Our results demonstrate the central role played by HIF-1α activity in deter-
mining the sensitivity or resistance of GBMs to TMZ, and we suggest that CMA is the 
cellular mechanism responsible for modulating this activity after TMZ treatment.
Keywords: theranostic biomarker, hypoxia-inducible factor-1α silencing, apoptosis, chaperone-mediated 
autophagy activity, temozolomide responsiveness
inTrODUcTiOn
Glioblastomas (GBMs) are the most frequently encountered astrocyte-derived brain tumors in adults 
and are characterized by highly aggressive behavior that leads to a poor prognosis (1). Despite the 
multimodal treatment approaches based on temozolomide (TMZ) chemotherapy and radiotherapy, 
the median survival of patients with GBM is approximately 14.6 months, and their 5-year survival 
rate is 4–5% (2).
Temozolomide exerts its anti-tumor action by methylating the O6 position of guanine residues, 
and these O-6-methylguanine (O-6-MG) adducts play a critical role in its activity by blocking gene 
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transcription, thus increasing GBM sensitivity to radiation and 
activating pro-autophagic and apoptotic processes (3, 4). Moreover, 
a functional relationship between apoptosis and autophagy in tumo-
rigenesis has also been described in relation to TMZ responses (4, 5).
Drug resistance is a major issue in the management of GBMs 
(6). It is now widely accepted that the methylation of the O- 
6-methylguanine DNA methyltransferase (MGMT) promoter 
is a biomarker of TMZ response as the enzyme antagonizes the 
effect of alkylating agents, thus counteracting their cytotoxicity 
and acting as a negative prognostic factor (7–9). However, there 
are other biomarkers that are capable of estimating the efficacy of 
TMZ (10–12): for example, we have proposed hypoxia-inducible 
factor (HIF)-1α activity as an early biomarker of response to TMZ 
in U251 GBM cells (13).
Hypoxia-inducible factor is related to a number of the charac-
teristics of GBMs involved in tumor progression, malignancy, and 
treatment resistance (14–16). It not only drives the expression of 
the genes involved in the response to hypoxia but also regulates 
the expression of genes that play a major role in other intracellular 
processes such as invasion, epithelial–mesenchymal transition, 
metastasis, dedifferentiation and maintenance of cancer stem 
cells, and genomic instability (17, 18). Recent studies (19, 20) have 
shown that HIF-1α downregulation reduces MGMT expression 
in GBM stem cells, thus suggesting a possible correlation between 
the two proteins (11, 19, 21–25), and we have previously shown 
that the negative modulation of HIF-1α is related to the response 
of U251 GBM cells to TMZ in vitro and in vivo (13).
The aim of this study was to investigate the role of HIF-1α 
activity as a biomarker of responsiveness to TMZ in a panel of 
glioma cell lines characterized by different MGMT methylation 
status and genetic background.
Hypoxia-inducible factor-1α degradation is due to the balance 
between the activity of the proteasome and chaperone-mediated 
autophagy (CMA) machinery (3, 26). CMA is a form of selective 
autophagy involved in the degradation of proteins containing a 
specific KFERQ-like motif. Different chaperone proteins such 
as Hsp90, STUB/CHIP, and Hsc70 cooperate in shuttling target 
proteins to specific lysosomes where, after LAMP-2A binding and 
multimerization, the KFERQ-containing proteins are unfolded 
and degraded. CMA regulation is mainly based on LAMP-2A 
localization and multimerization (27). As previous data show that 
TMZ induces autophagy (28, 29) and reduces HIF-1α activity 
(13) and that HIF-1α is a CMA target (30), we also investigated 
the role of CMA in modulating HIF-1α activity and, consequently, 
determining responsiveness or resistance to TMZ treatment.
Finally, the results of this study allow us to propose HIF-1α 
activity as an important therapeutic target in GBMs and to con-
sider it as a theranostic biomarker (10, 31–33).
resUlTs
TMZ Dose–response study confirmed  
the Different sensitivity to Treatment  
of the selected cell lines
Glioma cell lines showed different sensitivity to TMZ accord-
ing to their genetic background. Cell viability was determined 
by means of a Trypan blue exclusion test under normoxic and 
hypoxic conditions after exposure to increasing doses of TMZ 
for 24, 48, and 72 h. Under normoxic conditions, the U251 and 
U87 cells showed dose-dependent responsiveness to TMZ treat-
ment at each time point, even at very low drug concentrations 
(Figures 1A,B), whereas the T98 and U138 cells did not show any 
reduction in viability in response to treatment, thus confirming 
their TMZ resistance (Figures 1C,D). Under hypoxic conditions, 
the sensitivity of the responsive cells to TMZ was reduced: the 
TMZ dose required to induce a statistically significant reduc-
tion in cell viability was five times higher than under normoxic 
conditions (Figures 1A,B), whereas there was no change in the 
responsiveness of the TMZ-resistant cells (Figures 1C,D).
hiF activity as Biomarker of Treatment 
efficacy in glioma cells
As previous data from our group suggest that HIF activity may 
be biomarker of TMZ treatment efficacy in U251 cells (13), HIF-
1α expression and its nuclear translocation were investigated in 
all of the cell lines in relation to TMZ treatment and normoxic/
hypoxic conditions. HIF-1α activity was also monitored in the 
same cells by assessing the expression of the vascular endothelial 
growth factor (VEGF) transcript (an HIF target gene) and its 
extracellular release.
Hypoxia-inducible factor-1α expression decreased after 
TMZ treatment in the responsive U251 and U87 cells, but not 
in the resistant cells (Figure 2A). As expected, hypoxia induced 
an increase in HIF-1α expression in all of the cell lines. Under 
both conditions, TMZ treatment significantly reduced HIF-1α 
transcription only in the responsive cells, and the HIF-1α nuclear 
localization assay confirmed these observations (Figure 2B). In 
fact only in the TMZ-resistant T98 and U138 cells, nuclear HIF-
1α levels, even if increased in hypoxic conditions, were unaffected 
by TMZ treatment in both settings (Figure 2B). The modulation 
of HIF-1α activity was confirmed by the assessment of VEGF 
expression and release (Figures  2C,D). VEGF expression and 
release were positively modulated by hypoxia and negatively 
regulated by TMZ treatment only in the responsive cells, whereas 
only hypoxia modified VEGF levels in resistant cells.
The molecular consequences of the above culture conditions 
and treatments were analyzed by assessing apoptosis-related 
gene expression levels (Bax, Bad, and Bcl-2). Under normoxic 
conditions, TMZ treatment induced a reciprocal Bax/Bad vs 
Bcl-2 balance in sensitive and resistant cells, and their expression 
patterns were similar to those induced by hypoxia. Interestingly, 
the hypoxia-induced expression pattern was reverted by TMZ 
treatment only in the sensitive cells (Figure 2E). There was no 
difference in gene expression levels in the four cell lines under 
control conditions (Figure S1 in Supplementary Material).
hiF-1α but not hiF-2α impairment Was 
associated With TMZ
To investigate whether TMZ can modulate HIF-1α and HIF-
2α activity and expression, the two transcription factors were 
individually or concomitantly silenced in TMZ-sensitive and 
TMZ-resistant GBM  cells. TMZ treatment did not modulate 
FigUre 1 | Dose–response viability of responsive and resistant cells after temozolomide (TMZ) treatment. Cell viability was assessed by means of a Trypan blue 
exclusion test and expressed as the percentage of viable cells after 24, 48, or 72 h of treatment at increasing doses of TMZ under normoxic and hypoxic conditions. 
(a) U251, (B) U87, (c) T98, and (D) U138. **p < 0.01 TMZ-treated cells vs untreated cells. Mean values ± SD.
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HIF-2α expression in either cell type, but it downregulated HIF-
1α expression in sensitive cells and upregulated it in resistant cells 
(Figure 3A). The changes were independent of basal expression 
levels (Figure S2 in Supplementary Material).
Viability tests carried out after TMZ treatment and/or HIF-1α 
or HIF-2α silencing showed that the silencing of one or both 
HIF transcription factors alone did not reduce cell viability in 
any of the cell lines. After TMZ treatment, HIF-1α silencing did 
not lead to any further cell mortality beyond that obtained with 
TMZ treatment alone in the responsive U251 and U87 cell lines 
(Figure 3B). Otherwise, HIF-1α (but not HIF-2α) silencing sig-
nificantly decreased post-treatment cell viability in the resistant 
T98 and U138 cells (Figure 3C).
As expected, biochemical luciferase assay monitoring showed 
that HIF activity was reduced by TMZ only in sensitive cells, and 
further decreased after HIF-1α (but not HIF-2α) silencing. TMZ 
treatment alone did not reduce HIF-1α activity in resistant cells 
that was significantly reduced only in combination with HIF-1α 
silencing (Figures 3D,E). Silencing efficiency is shown in Figure 
S3 in Supplementary Material, which also shows that, under these 
conditions, luciferase expression and activity reflects HIF-1α but 
not HIF-2α activity.
The molecular consequences of HIF-1α silencing were 
evaluated by monitoring the expression of the apoptosis-related 
genes Bax, Bad, Trail, and Bcl-2. Again, TMZ induced an inverse 
modulation of pro- and anti-apoptotic genes in sensitive and 
resistant cells. However, HIF-1α silencing in sensitive cells did not 
induce any further modulation of apoptosis-related genes beyond 
that obtained after TMZ treatment but, interestingly, HIF-1α 
silencing in resistant cells restored a “sensitive-like pattern” in 
apoptosis-related gene expression, with the upregulation of Bax, 
Bad, and Trail expression, and a reduction in Bcl2 transcript levels 
(Figure 3F).
Temozolomide efficacy was also monitored after pharmaco-
logical HIF-1α activity impairment using BEZ235 and LY294002 
(PI3K/AKT inhibitors) and Trametinib (MAPK inhibitor).
Both in U251 and T98 cells, as expected, every treatment 
produced a statistically significant reduction in HIF-1α activity. 
In U251 TMZ-responsive cells, cell viability was impaired by all 
of the inhibitors. Moreover, although the high responsiveness to 
TMZ, comcomitant treatment with BEZ235 and Trametinib, pro-
duced a further decrease in cell viability after 24h (Figures 4A,B).
In T98 TMZ-resistant cells, as already reported after HIF-1α 
silencing, only concomitant treatments with TMZ produced a 
significant reduction in cell viability (Figures 4C,D).
hiF-1α Persistence induced by Blocking 
cMa reverts TMZ responsiveness  
in sensitive cells
Hypoxia-inducible factor-1α can be degraded by various 
mechanisms, one of which is the CMA machinery whose main 
player is LAMP-2A. TMZ treatment induced a reciprocal ratio 
of HIF-1α and LAMP-2A expression levels in TMZ-sensitive 
FigUre 2 | Temozolomide (TMZ) modulation of hypoxia-inducible factor (HIF)-1α expression and activity and apoptotic gene expression profiles in TMZ-sensitive 
and TMZ-resistant glioblastoma cells. (a) HIF-1α expression revealed by real-time PCR after 24 h treatment with TMZ 100 µM under normoxic and hypoxic 
conditions. The data were normalized to β-actin, and the ΔΔCt values were expressed as folds of induction (FOI). *p < 0.05; **p < 0.01 treated vs untreated  
cells. (B) ELISA-based HIF-1α nuclear quantification after TMZ treatment under normoxic and hypoxic conditions. The data are expressed as absorbance at 
450 nm. *p < 0.05 vs control under normoxic conditions; #p < 0.05 vs control under hypoxic conditions. (c) Vascular endothelial growth factor (VEGF) expression 
revealed by real-time PCR after treatment with TMZ 100 µM under normoxic and hypoxic conditions. The data were normalized as above. *p < 0.05; **p < 0.01 
TMZ-treated vs control cells under normoxic conditions; #p < 0.05, ##p < 0.01 TMZ-treated vs control cells under hypoxic conditions. (D) ELISA of the VEGF 
released by glioma cells in cell medium after TMZ treatment. *p < 0.05 TMZ-treated vs control cells under normoxic conditions; #p < 0.05 TMZ-treated vs control 
cells under hypoxic conditions. (e) The induction of pro-apoptotic (Bad and Bax) and anti-apoptotic genes (Bcl-2) was analyzed by means of real-time PCR in 
glioma cells treated with TMZ under normoxic and hypoxic conditions. The data were normalized to β-actin, and the ΔΔCt values were expressed as the ratio 
between the mean values in the responsive and resistant cells (FOI). *p < 0.05; **p < 0.01; ***p < 0.001 treated vs control cells. Mean values ± SD of three 
independent experiments.
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FigUre 3 | Continued
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and TMZ-resistant cells (Figure 5A), whereas no difference was 
found in the same cell lines under control conditions (Figure S4 in 
Supplementary Material). With the aim of investigating the role 
of CMA in TMZ responsiveness, LAMP-2A was silenced, and the 
effect of TMZ was monitored by assessing cell viability, HIF-1α 
activity, and the modulation of apoptosis-related genes (silencing 
FigUre 4 | Cell viability and hypoxia-inducible factor (HIF)-1α activity after treatment with different HIF-1α inhibitors and temozolomide (TMZ). The viability of U251 
(a) and T98 (c) was assessed by means of Trypan blue exclusion test and expressed as the percentage of viable cells after HIF-1α inhibitors. For U251 cells, all 
treatments are statistically significant vs control cells ***p < 0.001; #p < 0.05; ###p < 0.001 HIF-1α inhibitors vs TMZ treatment. For T98, **p < 0.01; ***p < 0.001 
treated vs control cells; ###p < 0.001 treatments vs TMZ treatment. HIF-dependent luciferase activity was analyzed in cell lysates, and expressed as the percentage 
variation in relative luminescence units (RLUs) in U251 (B) and T98 (D) cells. All treatments are statistically significant vs control cells ***p < 0.001; #p < 0.05; 
##p < 0.01; ###p < 0.001 HIF-1α inhibitors vs TMZ treatment.
FigUre 3 | Hypoxia-inducible factor (HIF)-1α silencing induces a responsive-profile in temozolomide (TMZ)-resistant cells. (a) The expression of HIF-1α and HIF-2α 
was evaluated by means of real-time PCR after TMZ treatment in all of the cell lines. The data were normalized to β-actin, and the ΔΔCt values were expressed as 
folds of induction (FOI) **p < 0.01 treated vs control cells. ##p < 0.01 HIF-1α in resistant vs sensitive cells. (B,c) The viability of U251 and U87 (B) and T98 and U138 
cells (c) was assessed by means of Trypan blue exclusion test, and expressed as the percentage of viable cells after HIF-1α or HIF-2α silencing. *p < 0.05, 
**p < 0.01, ***p < 0.001 vs control cells. (D,e) HIF-dependent luciferase activity was analyzed in cell lysates, and expressed as the percentage variation in relative 
luminescence units (RLUs). *p < 0.05; **p < 0.01; ***p < 0.001 vs control cells; #p < 0.05 siRNA + TMZ vs TMZ. (F) After silencing, the cells were treated with TMZ 
and the induction of Bax, Bad, Trail, and Bcl-2 genes was analyzed by means of real-time PCR. The data were normalized to β-actin, and the ΔΔCt values were 
expressed as FOI of the ratio between treated and control cells. Results of sensitive and resistant cells were presented as FOI mean values ± SD. *p < 0.05; 
**p < 0.01; ***p < 0.001 treated vs control cells. Mean values ± SD of three independent experiments.
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efficiency is shown in Figure S5 in Supplementary Material). 
LAMP-2A silencing alone did not induce any significant change 
in cell viability or HIF-1α activity in both TMZ-sensitive and 
TMZ-resistant cell lines (Figures  5B,C). However, LAMP-2A 
silencing in TMZ-treated sensitive cells was accompanied by the 
acquisition of resistant-like behavior characterized by increased 
cell survival after treatment and increased HIF-1α activity. This 
effect was not observed in the resistant cells.
LAMP-2A downmodulation did not change the expression 
profile of TMZ-resistant T98 cells after TMZ treatment, but 
LAMP-2A silencing induced a profound change in the expression 
of apoptosis-related genes in TMZ-treated U251 cells that led to a 
“resistant-like pattern” and confirmed the results of the viability 
assay (Figure 5D).
DiscUssiOn
This study investigated the role played by HIF-1α activity in 
the susceptibility of GBMs to TMZ treatment, and its role as an 
early biomarker of tumor response to this drug and has led to us 
FigUre 5 | LAMP-2A silencing induces a resistant-profile in temozolomide (TMZ)-sensitive cells. (a) The expression of hypoxia-inducible factor (HIF)-1α and 
LAMP-2A was measured in the U251 and T98 cell lines after TMZ treatment. The data were normalized to β-actin, and the ΔΔCt values were expressed as folds of 
induction (FOI). (B) After silencing, the cells were treated with TMZ and the induction of Bax, Bad, Trail, and Bcl-2 genes was analyzed by means of real-time PCR. 
The data were normalized to β-actin, and the ΔΔCt values were expressed as FOI of the ratio between treated and untreated cells. *p < 0.05; **p < 0.01; 
***p < 0.001 treated vs control cells; #p < 0.05; ##p < 0.01 siRNA LAMP-2A vs TMZ. 1p < 0.05 siRNA LAMP-2A + TMZ vs TMZ. (c) The viability of U251 and T98 
cells was assessed by means of Trypan blue exclusion test, and expressed as the percentage of viable cells after single or combined treatment **p < 0.01 treated vs 
control cells. (D) HIF-1α-dependent luciferase activity was analyzed in cell lysates and expressed as the percentage change in relative luminescence units (RLUs) 
**p < 0.01 treated vs control cells. Mean values ± SD of three independent experiments.
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proposing that CMA is the mechanism responsible for modulat-
ing such activity.
MGMT methylation has become the main prognostic factor 
in GBM patient management (8, 34), but some cases have been 
reported in which MGMT-methylated cells are resistant to 
TMZ and MGMT-expressing cells are sensitive to the drug. This 
variability suggests that other, still unknown mechanisms, may 
be involved in TMZ resistance/responsiveness. Suggested GBM 
genetic biomarkers of the efficacy of TMZ (35) include isocitrate 
dehydrogenase 1 and 2 (IDH1/2) gene mutations and 1p and 19q 
chromosomal co-deletions (36, 37) which have acquired clinical 
relevance because of their diagnostic, prognostic, and sometimes 
predictive value even though they are still related to the status 
of genome methylation (9, 11, 12). There is therefore a need to 
identify new and early biomarkers capable of estimating the 
responsiveness of GBMs to TMZ that take into account other 
aspects of the tumors.
With the aim of identifying the cellular mechanisms involved 
in responses to TMZ, we analyzed four different human GBM cell 
lines and found that TMZ concentrations capable of inducing a 
statistically significant reduction in cell viability increase under 
hypoxic conditions. These data, together with previous findings 
by Lo Dico et al. (13) showing that a significant reduction in HIF-
1α activity precedes a response to TMZ treatment in GBM cells, 
led us to explore this activity further, and we found that changes 
in HIF-1α activity correlate with TMZ-induced changes in the 
viability of TMZ-sensitive and TMZ-resistant cells under both 
normoxic and hypoxic conditions. The modulation of HIF-1α 
activity after TMZ treatment in all of the cell lines correlated 
HIF-1α nuclear translocation and the expression and release of 
its direct target VEGF, thus confirming previous results and the 
important consequences of this modulation on responsiveness. 
Our assessment of apoptosis-related gene balance after TMZ 
treatment under both normoxic and hypoxic conditions allowed 
us to delineate a reciprocal expression pattern in TMZ-sensitive 
and TMZ-resistant cells. The fact that hypoxia induced an expres-
sion pattern similar to that induced by TMZ treatment in resist-
ant cells, in both cell types, provides a further clue concerning the 
importance of HIF-1α activity in GBM responsiveness to TMZ.
The HIF family not only includes the well-known HIF-1α and 
HIF-1β proteins but also other members such as HIF-2α, which 
has attracted a certain interest as it is induced by chronic hypoxia, 
FigUre 6 | This graphical abstract explains hypoxia-inducible factor (HIF)-1α/chaperone-mediated autophagy (CMA) relation with glioblastoma responsiveness  
to temozolomide (TMZ).
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and is involved in the regulation of metabolism and angiogenesis 
(38–40), and the maintenance of the stem niche, which suggests it 
is related to an aggressive profile (41). Our current findings demon-
strate that HIF-1α (but not HIF-2α) expression can be modulated 
by TMZ treatment and that only HIF-1α modulation is responsible 
for GBM responsiveness to the drug. This thesis is strengthened 
by HIF-1α silencing experiments in resistant cells post-TMZ treat-
ment: cell viability assay show that HIF-1α downmodulation alone 
is a necessary and sufficient condition for restoring drug respon-
siveness. The TMZ treatment of resistant cells in which HIF-1α is 
silenced, increases the transcription of pro-apoptotic genes, and 
concomitantly decreases Bcl-2 expression, thus re-establishing a 
“sensitive-like” gene expression pattern.
Hypoxia-inducible factor-1α degradation through CMA 
is mainly due to LAMP-2A activity (30). As TMZ induces 
autophagy and HIF-1α possesses the KFERQ-like target motif 
needed for CMA degradation (29, 30), we hypothesized (and 
have subsequently demonstrated) that inhibiting CMA by silenc-
ing LAMP-2A not only inhibits HIF-1α downmodulation in 
sensitive GBM cells but it is also correlates with their acquisition 
of “TMZ-resistant behavior.”
The consistency in the modulation of Bcl-2 expression 
observed in relation to the efficacy of TMZ treatment and after 
the modulation of HIF-1α activity (HIF-1α or LAMP-2A silenc-
ing and TMZ treatment) provides evidence of the key role played 
by HIF-1α activity as a switch between cell survival and cell death 
after TMZ treatment (42, 43).
Emerging evidence has shown that HIF-1α activity plays a fun-
damental role in many different tumors as it is not only involved in 
cell responses to hypoxia but also in cell bioenergetic balance, the 
maintenance of stemness, and invasiveness (44–46). For example, 
it has been reported that the metastatic potential of breast cancer 
is increased in patients undergoing anti-angiogenic therapy, pos-
sibly because of positive modulation of HIF-1α activity under 
hypoxic conditions. These data are in line with the observation 
that 25–40% of invasive breast cancer samples are positive for 
hypoxia markers (47–49). HIF-1α is also an important prognostic 
indicator in clear cell renal carcinoma (50) and recent studies have 
shown that it plays a role in the pathophysiological evaluation of 
gliomas as HIF-1α silencing combined with radiation therapy 
increases the therapeutic efficacy of glioma treatment by regulat-
ing cell cycle- and apoptosis-related signaling pathways (51, 52).
TaBle 2 | Primer sequences.
gene Forward reverse
BAX 5′-AGGGTGGCTGGGAAGGC-3′ 3′- TGAGCGAGGCGGTGAGG-5′
BAD 5′-CCCAGAGTTTGAGCCGAGTG-3′ 3′-CCCATCCCTTCGTCGTCCT-5′
HIF-1α 5′-TGATTGCATCTCCATCTCCTAC-3′ 3′-GACTCAAAGCGACAGATAACACG-5′
HIF-2α 5′-CTTTTCGGGTCTGACAGCCT-3′ 3′-TGTGTTCGCAGGAAGCTGAT-5′
VEGF 5′-CGAGGGCCTGGAGTGTGT-3′ 3′-CGCATAATCTGCATGGTGATG-5′
TRAIL 5′-GCTCTGGGCCGCAAAAT-3′ 3′-TGCAAGTTGCTCAGGAATGAA-5′
Bcl-2 5′-GATTGTGGCCTTCTTTGAG-3′ 3′-CAAACTGAGCAGAGTCTTC-5′
LAMP-2A 5′-TGCTGGCTACCATGGGGCTG-3′ 3′-GCAGCTGCCTGTGGAGTGAGT-5′
β-ACTIN 5′-ATCAAGATCATTGCTCCTCCTG-3′ 3′-CTGCTTGCTGATCCACATCTG-5′
TaBle 1 | Glioma cell genetic profiles.
cell line classification MgMT methylation status (19) PTen p53
U251 Glioblastoma 
(GBM)
Methylated Mut Mut
U87 GBM Methylated Mut Wt
T98 GBM Quite methylated Mut Mut
U138 GBM Rarely methylated Mut Mut
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In the same way, it has been previously demonstrated that 
there is a connection between the abrogation of HIF-1α activity 
and reduced tumor cell viability and migration, reducing conse-
quently also the metastatic potential (45).
For this reason, a number of HIF-1α inhibitors have been used 
in combination with standard chemotherapy to treat melanomas 
(53), breast cancer (54), and GBMs (55) in clinical trials in which 
it has been found that HIF-1α inhibition increases tumor response 
to treatment and leads to a reduction of the tumor progres-
sion rate, thus making it an interesting new therapeutic option 
(24, 56–58). The same results have been obtained herein in U251 
and T98 cells with different small molecules able to reduce HIF-
1α activity. Further studies will be needed to understand which 
molecule is able to produce the highest synergy in combination 
with TMZ, minimizing off-target effects.
In conclusion, our findings demonstrate the central role of 
HIF-1α activity in maintaining the TMZ resistance of GBM cells, 
and that CMA activity is the main mechanism mediating HIF-1α 
modulation and GBM responsiveness to TMZ (Figure 6).
MaTerials anD MeThODs
cell lines and reagents
The U251 cells were routinely maintained in RPMI 1640 medium, 
the U87 cells in Dulbecco’s modified Eagle’s medium, and the T98 
and U138 cells in Eagle’s minimum essential medium. All of the 
media were supplemented with 10% heat-inactivated fetal bovine 
serum, penicillin and streptomycin (50  IU/mL), and 2  mM 
glutamine (all Euroclone, Italy). The cells were maintained in a 
humidified atmosphere of 5% CO2 at 37°C. For hypoxia experi-
ments, all media were complemented with 25 mM HEPES Buffer 
to avoid media de-acidification in the absence of CO2.
Hypoxia-inducible factor-1α inhibitors were used as follow: 
1 µM BEZ235 (for 48 h, SelleckChem, Houston, TX, USA), 50 µM 
LY294002 (Sigma-Aldrich), and 10  µM Trametinib (for 72  h, 
SelleckChem). All drugs were re-suspended in dimethyl sulfoxide 
in accordance with the manufacturer’s instructions.
The cell profiles are shown in Table 1.
cell Viability assay
In vitro treatments were used to evaluate dose-dependent TMZ 
efficacy: 10,000 cells/cm2 were seeded in complete medium and 
treated for 24 h with TMZ 0.1–200 µM (Sigma-Aldrich, St. Louis, 
MO, USA), and cell viability was evaluated using the Trypan blue 
exclusion test. During the hypoxia experiments, 10,000  seeded 
cells/cm2 were incubated in a hypoxic chamber containing a 1% 
O2 gas mixture. In all the other experiments, the TMZ dose used 
was 100 µM.
rna extraction and real-Time Pcr
RNA was extracted using a commercially available Illustra 
RNA spin Mini Isolation Kit (GE Healthcare, Milan, Italy) in 
accordance with the manufacturer’s instructions. Total RNA 
was reverse-transcribed to cDNA using a High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Monza, Italy). 
The real-time PCRs were performed in triplicate for each data 
point using the Sybr Green technique; the oligonucleotides used 
are shown in Table 2. The changes in target mRNA content in 
relation to the β-actin housekeeping gene were determined using 
the ΔΔCt method.
hiF-1 nuclear Quantification
An ELISA-based kit (TransAM Kit, Vinci-Biochem, Vinci, Italy) 
was used to detect and quantify HIF-1α transcriptional factor 
activity in accordance with the manufacturer’s instructions. The 
data are expressed as the amount of HIF-1α protein in nuclear 
extract (OD 450 nm).
elisa assay
The concentration of VEGF in glioma cell-conditioned medium 
was quantified using an ELISA kit (VEGF Human ELISA 
KitNovex®, Cat. No. KHG011, Life Technologies, Monza, Italy) 
in accordance with the manufacturer’s protocol. The medium was 
collected under normoxic conditions and after hypoxia treatment 
also after TMZ treatment. The data are expressed in pg/mL.
sirna Transfection
Glioma cells were transfected with 10 nM of HIF-1α (Cat. No. 
GS3091, Qiagen, Milan, Italy) and/or EPASa/HIF-2α siRNA (Cat. 
10
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No. GS2034, Qiagen) or a scrambled negative control (Product 
No. 1027280, Qiagen) using the Attractene Transfection Reagent 
(Cat. No. 301005, Qiagen) as indicated by the manufacturer. 
The cells used for LAMP-2A silencing were transfected 
with LAMP-2A siRNA or a scrambled negative control. 
LAMP-2A siRNA was custom made by Eurofins (Vimodrone, 
Italy).
Bioluminescent assay
For cell transfection, the glioma cell lines were seeded at 
10,000 cells/cm2 and transfected with 1 µg of pHRE-luciferase 
plasmid. Twenty-four hours after transfection, the medium was 
collected, and the cells were processed for subsequent assay. 
The cells were analyzed using the GloMax-Multi Detection Sys-
tem (Promega, Milan, Italy). Protein content was measured by 
means of a Bradford assay, and the bioluminescence signal was 
normalized to milligrams of protein and expressed as relative 
luminescence units (RLUs = luciferase counts per milligram of 
proteins).
statistical analysis
The in  vitro experiments were repeated three times and led 
to reproducible results. The data are presented as the mean 
values ±  SD of three independent experiments and were sta-
tistically analyzed using a t test or one- or two-way analysis 
of variance, followed by Dunnett’s or Bonferroni’s multiple 
comparison and Prism 4 software (GraphPad Software Inc., San 
Diego, CA, USA).
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